Decimal.health was featured in an article by the Mobihealth news about the panel presentation at HIMSS23 that Kamal Jethwani participated in.
The article discusses the potential of digital therapeutics (DTx) to transform healthcare by providing evidence-based treatments through software programs. However, despite the promising results of some DTx, the industry still faces challenges in gaining acceptance from healthcare providers and insurers. The article highlights the need for DTx to demonstrate their effectiveness through rigorous clinical trials and to integrate with existing healthcare systems to ensure proper patient monitoring and data sharing. Additionally, the article emphasizes the importance of ensuring that DTx are accessible and affordable to patients who need them. Ultimately, the article argues that DTx has the potential to greatly benefit clinical care but must overcome barriers to adoption in order to succeed.
Related Articles
Innovation Estonia : DTX Estonia 2023
Dr.Kamal Jethwani, Managing Partner and CEO, Decimal.health shares some powerful insights from his week-long experiences at DTx Estonia 2023 where he delved into the dynamic world of digital health and entrepreneurship!
Remote Patient Monitoring: It’s Not New But it’s Necessary
In response to the COVID-19 pandemic, the United States (US) healthcare industry embraced remote patient monitoring devices to deliver clinically effective and safe care in the comfort of patients’ homes. Remote patient monitoring (RPM) offered the double benefit of reducing the burden on an.
Can RPM/RTM Codes Solve the Provider Adoption Problem for Digital Therapeutics?
Globally, the Remote Patient Monitoring (RPM) market is valued at USD $4.4B (2022) and is expected to register a compound annual growth rate (CAGR) of 18.5% by 2030 (GrandViewResearch). As one of the largest healthcare markets, the US holds over 40% of the revenue share for the RPM market (.